PATENT CLAIM ANALYSIS

Application Number: 16040405
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "217000"]

Abstract:
The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering α-methyl-DL-tyrosine.

Claim (Index 1):
A method for providing a plasma concentration of a therapeutic drug for a long term for treating an autism in a subject in need thereof, the method comprising administering to said subject said therapeutic drug at a concentration ranging from about 50 mg (w/w) to about 1500 mg (w/w) daily, wherein said therapeutic drug is \u03b1-methyl-DL-tyrosine, wherein said plasma concentration ranges from about 500 ng/ml to 5000 ng/ml, and wherein said term is at least 1 week.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 95.0
- Lexical Diversity: 1.3
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15524334', '15029596', '15059602', '14415978', '13945384']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7192693376490671
- 35 USC 102 Novelty (BERT): 0.5261861587108675
- Combined Prediction Score: 0.6999610197552472
- Mean Citation Score: 254.371296
- Max Citation Score: 299.7217
- Similarity Product: 190.1008240840435

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test